Tag
This review synthesizes current evidence on subsolid nodules (SSNs) and ground-glass opacities (GGOs), focusing on their natural history, treatment strategies including ablation and surgery, survival outcomes, and mortality causes. It highl
This retrospective study demonstrates that radiofrequency ablation (RFA) effectively treats low-risk papillary thyroid microcarcinomas (PTMC), including those with intratumoral calcifications, with excellent technical success, significant t
This review synthesizes evidence comparing laparoscopic radiofrequency ablation and myomectomy for uterine leiomyomata, highlighting higher treatment failure rates with RFA and identifying predictive factors influencing outcomes.
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
Radiofrequency ablation (RFA) provides a safe, effective treatment for thyroid nodules in the remaining lobe after unilateral thyroid lobectomy, offering substantial volume reduction with minimal complications and preserved thyroid function
This prospective registry reveals a significantly increased risk of stroke or transient ischemic attack within 30 days after pulsed field ablation compared to radiofrequency ablation for atrial fibrillation, highlighting important safety co
This study quantitatively compares the direct healthcare costs of thyroid radiofrequency ablation (RFA) and hemithyroidectomy over one year, revealing cost advantages of RFA driven by reduced facility use, tempered by factors like repeat pr
A large Latin American study shows radiofrequency ablation is a safe, effective minimally invasive alternative for T1a low-risk papillary thyroid cancer, with excellent tumor disappearance rates and minimal complications over 18 months foll
The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.
The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.
